Cronos Group (TSE:CRON) had its price target boosted by equities research analysts at GMP Securities from C$14.00 to C$24.00 in a note issued to investors on Monday. GMP Securities’ target price would indicate a potential upside of 40.19% from the company’s current price. Separately, Canaccord Genuity increased their target price on Cronos Group from C$9.00 to C$17.00 in a report on Monday.
Dec 12 2018 TSE:CRON opened at C$17.12 on Monday. The company has a debt-to-equity ratio of 2.58, a quick ratio of 5.74 and a current ratio of 9.02. Cronos...
https://www.tickerreport.com/banking-finance/4008685/cronos-group-cron-pt-raised-to-c24-00.html
Wednesday, January 2, 2019
GMP Securities raises CRON from C$14.00 to C$24.00
Monday, December 31, 2018
Post/CP say Aphria rejects Xanthic's overtures
Post/CP say Aphria rejects Xanthic's overtures
Aphria Inc (C:APHA)
Shares Issued 249,762,289
Last Close 12/28/2018 $8.52
Shares Issued 249,762,289
Last Close 12/28/2018 $8.52
Monday December 31 2018 - In the News
The Financial Post reports in its Saturday edition that Aphria shares shot up as much as 14 per cent early Friday before easing back as investors responded to an American company's takeover proposal that valued the cannabis company at $2.8-billion.
A Canadian Press dispatch to the Post says that Aphria shares were off their early highs at $8.46 after 30 minutes of trading at the Toronto Stock Exchange, up 89 cents from Thursday's close at $7.57. Ohio-based Xanthic Biopharma, which does business as Green Growth Brands, announced after Thursday's close that its offer valued its own shares at $7 each and Aphria shares at $11 per share. Aphria responded before markets opened on Friday, saying the actual value of Xanthic shares is substantially lower than the announced offer price and, at current market rates, undervalues the Leamington, Ont., cannabis producer. In early trading Friday,
Xanthic shares fell 7 per cent to $4.60, down 38 cents, at the Canadian Securities Exchange. At that price, its offer of 1.5714 Xanthic shares would value Aphria shares at about $7.23.
Aphria said in a statement Friday that "their proposal falls short of rewarding our shareholders for participating in such a transaction."
© 2018 Canjex Publishing Ltd.
Unfortunately, Mr. Hodson says no end is in sight. As long as (a) investors continue to panic, and rush to sell any stock targeted by short sellers, and (b) regulators do nothing, then we are likely to continue to see Canadian companies attacked by "short and distort" reports posted on the Internet.
Unfortunately, Mr. Hodson says no end is in sight. As long as (a) investors continue to panic, and rush to sell any stock targeted by short sellers, and (b) regulators do nothing, then we are likely to continue to see Canadian companies attacked by "short and distort" reports posted on the Internet.
Subscribe to:
Posts (Atom)